Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | M1043I |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | PIK3CA M1043I lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). M1043I confers a gain of function on the Pik3ca protein as indicated by in increased phosphorylation of Akt, activation of downstream signaling, and transformation in cell culture (PMID: 17376864, PMID: 29533785). |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA M1043I PIK3CA mutant PIK3CA exon21 PIK3CA M1043I |
Transcript | NM_006218.4 |
gDNA | chr3:g.179234286G>C |
cDNA | c.3129G>C |
Protein | p.M1043I |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_006218 | chr3:g.179234286G>C | c.3129G>C | p.M1043I | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179234286G>C | c.3129G>C | p.M1043I | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179234286G>C | c.3129G>C | p.M1043I | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179234286G>C | c.3129G>C | p.M1043I | RefSeq | GRCh38/hg38 |
XM_011512894 | chr3:g.179234286G>C | c.3129G>C | p.M1043I | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179234286G>C | c.3129G>C | p.M1043I | RefSeq | GRCh38/hg38 |
XM_006713658.5 | chr3:g.179234286G>C | c.3129G>C | p.M1043I | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179234286G>C | c.3129G>C | p.M1043I | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA M1043I | endometrial adenocarcinoma | no benefit | Copanlisib | Case Reports/Case Series | Actionable | In a Phase II (NRG-GY008) trial, Aliqopa (copanlisib) was well tolerated but demonstrated limited efficacy, resulted in stable disease in a patient with endometrioid adenocarcinoma harboring PIK3CA M1043I (PMID: 31934607). | 31934607 |
PIK3CA M1043I | lung squamous cell carcinoma | no benefit | Taselisib | Case Reports/Case Series | Actionable | In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet its primary endpoint for response rate in patients with lung squamous cell carcinoma harboring PIK3CA mutations, resulting in no response in a patient harboring PIK3CA M1043I (PMID: 31158500; NCT02785913). | 31158500 |